circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Peterson JA, Kusunose M, Kusunose E, Coon MJ (1967). "Enzymatic omega-oxidation. II. Function of rubredoxin as the electron carrier in omega-hydroxylation". J. Biol. Chem. 242 (19): 4334–40. doi:10.1016/S0021-9258(18)99543-8. PMID 4294330. "Enzymatic -oxidation. VI. Isolation of homogeneous reduced diphosphopyridine nucleotide-rubredoxin reductase". J. Biol. Chem. 247 (7): 2109–16. 1972. PMID 4335861. Ueda T, Coon MJ (1972). "Enzymatic oxidation. VII. Reduced diphosphopyridine nucleotide-rubredoxin reductase: properties and function as an electron carrier in hydroxylation". J. Biol. Chem. 247 (16): 5010–6. doi:10.1016/S0021-9258(19)44932-6. PMID 4403503. Petitdemange H, Marczak R, Blusson H, Gay R (1979). "Isolation and properties of reduced nicotinamide adenine dinucleotiderubredoxin oxidoreductase of Clostridium acetobutylicum". Biochem. Biophys. Res. Commun. 91 (4): 1258–65. Bibcode:1979BBRC...91.1258P. doi:10.1016/0006-291X(79)91202-6. PMID 526302.
The mortality rate from variola minor is approximately 1%, while the mortality rate from variola major is approximately 30%. Ordinary type-confluent is fatal about 50–75% of the time, ordinary-type semi-confluent about 25–50% of the time, in cases where the rash is discrete the case-fatality rate is less than 10%. The overall fatality rate for children younger than 1 year of age is 40–50%. Hemorrhagic and flat types have the highest fatality rates. The fatality rate for flat or late hemorrhagic type smallpox is 90% or greater and nearly 100% is observed in cases of early hemorrhagic smallpox. The case-fatality rate for variola minor is 1% or less. There is no evidence of chronic or recurrent infection with variola virus. In cases of flat smallpox in vaccinated people, the condition was extremely rare but less lethal, with one case series showing a 67% death rate. In fatal cases of ordinary smallpox, death usually occurs between days 10–16 of the illness. The cause of death from smallpox is not clear, but the infection is now known to involve multiple organs. Circulating immune complexes, overwhelming viremia, or an uncontrolled immune response may be contributing factors. In early hemorrhagic smallpox, death occurs suddenly about six days after the fever develops. The cause of death in early hemorrhagic cases is commonly due to heart failure and pulmonary edema. In late hemorrhagic cases, high and sustained viremia, severe platelet loss and poor immune response were often cited as causes of death.
During the 1970s, the expansion of Arby's took place at a rate of 50 stores per year. During this time it created several menu items, including the Beef 'n Cheddar, Jamocha Shakes, chicken sandwiches, curly fries, and two signature sauces: Arby's Sauce and Horsey Sauce. Baked potatoes were added to the menu in 1985. Curly fries were initially introduced as Curly-Q Fries in 1988. It became the first restaurant in the fast food industry to offer a complete "lite" menu in 1991 with several sandwiches and salads under 300 calories and 94 percent fat-free. The family-owned business tried converting into a public company in 1970 by offering the sale of stock, but the IPO never went through when the stock market subsequently fell. Arby's filed for reorganization with the United States bankruptcy court in February 1971, owing to a large number of debts accrued in expansion, as well as a nationwide recession and relatively high price point compared to other fast-food chains of the time. In 1976, the family sold the company to RC Cola for $18 million and Leroy Raffel remained as CEO until his retirement three years later. In 1984, Victor Posner obtained Arby's via a hostile takeover of its then parent Royal Crown through his DWG Corporation. Nine years later, with a new owner of DWG Corporation and a new name, Triarc Companies, Inc., a former PepsiCo executive, Don Pierce, was brought in to "resurrect" Arby's. With $100 million additional funding, Pierce moved to a new "Roast Town" concept, similar in format to Boston Market, in 1996.
Lactococcus lactis is a gram-positive bacterium used extensively in the production of buttermilk and cheese, but has also become famous as the first genetically modified organism to be used alive for the treatment of human disease. L. lactis cells are cocci that group in pairs and short chains, and, depending on growth conditions, appear ovoid with a typical length of 0.5 - 1.5 μm. L. lactis does not produce spores (nonsporulating) and are not motile (nonmotile). They have a homofermentative metabolism, meaning they produce lactic acid from sugars. They've also been reported to produce exclusive L-(+)-lactic acid. However, reported D-(−)-lactic acid can be produced when cultured at low pH. The capability to produce lactic acid is one of the reasons why L. lactis is one of the most important microorganisms in the dairy industry. Based on its history in food fermentation, L. lactis has generally recognized as safe (GRAS) status, with few case reports of it being an opportunistic pathogen. Lactococcus lactis is of crucial importance for manufacturing dairy products, such as buttermilk and cheeses. When L. lactis ssp. lactis is added to milk, the bacterium uses enzymes to produce energy molecules (ATP), from lactose. The byproduct of ATP energy production is lactic acid. The lactic acid produced by the bacterium curdles the milk, which then separates to form curds that are used to produce cheese.
Goldman's dilemma, or the Goldman dilemma, is a question that was posed to elite athletes by physician, osteopath and publicist Bob Goldman, asking whether they would take a drug that would guarantee them success in sport, but cause them to die after five years. In his research, as in previous research by Mirkin, approximately half the athletes responded that they would take the drug, but modern research by James Connor and co-workers has yielded much lower numbers, with athletes having levels of acceptance of the dilemma that were similar to the general population of Australia.
Sources: en.wikipedia.org
Glycolysis – The first stage is known as glycolysis, which produces 2 ATP molecules, 2 reduced molecules of nicotinamide adenine dinucleotide (NADH) and 2 pyruvate molecules that move on to the next stage – the Krebs cycle. Glycolysis takes place in the cytoplasm of normal body cells, or the sarcoplasm of muscle cells. The Krebs cycle – This is the second stage, and the products of this stage of the aerobic system are a net production of one ATP, one carbon dioxide molecule, three reduced NAD+ molecules, and one reduced flavin adenine dinucleotide (FAD) molecule. (The molecules of NAD+ and FAD mentioned here are electron carriers, and if they are reduced, they have had one or two H+ ions and two electrons added to them.) The metabolites are for each turn of the Krebs cycle. The Krebs cycle turns twice for each six-carbon molecule of glucose that passes through the aerobic system – as two three-carbon pyruvate molecules enter the Krebs cycle. Before pyruvate enters the Krebs cycle it must be converted to acetyl coenzyme A. During this link reaction, for each molecule of pyruvate converted to acetyl coenzyme A, a NAD+ is also reduced. This stage of the aerobic system takes place in the matrix of the cells' mitochondria. Oxidative phosphorylation – The last stage of the aerobic system produces the largest yield of ATP – a total of 34 ATP molecules. It is called oxidative phosphorylation because oxygen is the final acceptor of electrons and hydrogen ions (hence oxidative) and an extra phosphate is added to ADP to form ATP (hence phosphorylation).
The total ion current chromatogram (TICC) represents the summed intensity across the entire range of masses being detected at every point in the analysis. The range is typically several hundred mass-to-charge units or more. In complex samples, the TICC often provides limited information as multiple analytes elute simultaneously, obscuring individual species.
In 2000, it acquired Brazilian appliance maker Multibrás, owner of the brands Brastemp and Consul, including its stake in Embraco. In 2001, Inglis Ltd. changed its name to Whirlpool Canada. Whirlpool continues to market Inglis appliances to this day.
== Tissue distribution == IGFBP-3 mRNA is expressed in all tissue examined, with kidney, stomach, placenta, uterus and liver showing highest expression in rat tissues. Rat liver IGFBP-3 mRNA is found in nonparenchymal cells including sinusoidal endothelium, but not in hepatocytes. In contrast, human hepatocytes do express IGFBP-3.
Following a Round 22 61-point demolition at the hands of lower-placed Hawthorn, Thompson's job was under immense pressure. After a very public review of the club, it was decided that Thompson should keep his job as senior coach. After a shaky start to the 2007 season that led many supporters to believe that nothing had changed from the 2006 season, Thompson led Geelong to a massive 15 match winning streak (the biggest in a single season in club history) and a 106-point win against the Kangaroos in the Qualifying Final which is the 5th biggest finals winning margin in AFL/VFL history. The 2007 season then culminated in one of the biggest, if not the best highlight of Thompson's career, in both a coaching and footballer's role. Thompson coached Geelong to win the AFL premiership in the 2007 AFL Grand Final by more than 100 points, which was the highest winning margin in Grand Final history, against Port Adelaide Football Club at the MCG on 29 September. It was the club's first premiership since 1963, the year of Thompson's birth. After the Essendon Football Club decided not to give Thompson's former mentor, Kevin Sheedy, a renewal of contract, there was speculation that Mark Thompson would take up the senior coaching role at Essendon for the 2008 season. However, with trade week quickly approaching, the club instead appointed Matthew Knights to the position. After Geelong's record-breaking win in the grand final, Geelong under Thompson were red hot favourite to repeat their 2007 success in the 2008 season and their form during the year did nothing to change that.
Sources: en.wikipedia.org
=== Selenium sulfide === Selenium sulfide slows down epidermal proliferation. It is fungicidal to Pityrosporum ovale. It also acts as a keratolytic. Selenium sulfide is also known to reduce dryness of scalp and folliculitis. Systemic toxicity can appear if it is applied to inflamed skin. Hypersensitivity reactions are noted in some people.
=== 1985 === February 6: The Reagan Doctrine commits the United States of America to supporting anti-Communist insurgencies in the Third World. March 10: General Secretary of the Communist Party of the Soviet Union Konstantin Chernenko dies. March 11: Mikhail Gorbachev becomes leader of the Soviet Union. March 15: Military rule ends in Brazil. March 24, 1985: Major Arthur D. Nicholson, a US Army Military Intelligence officer is shot to death by a Soviet sentry in East Germany. He is listed as the last US casualty in the Cold War. April 11: Enver Hoxha dies. Ramiz Alia takes over as First Secretary of the Party of Labor of Albania, becoming the de facto leader of Albania. April 22: The Trial of the Juntas convenes to prosecute the members of the National Reorganization Process (the military junta that governed Argentina from 1976 to 1983) for war crimes and crimes against humanity committed during its existence. May 20: John Anthony Walker is arrested by the FBI. August 6: Coinciding with the 40th anniversary of the atomic bombings of Hiroshima and Nagasaki, the Soviet Union begins what it has announced is a 5-month unilateral moratorium on the testing of nuclear weapons. The Reagan administration dismisses the dramatic move as nothing more than propaganda and refuses to follow suit. Gorbachev declares several extensions, but the United States fails to reciprocate, and the moratorium comes to an end on February 5, 1987. November 7: Crisis of Sigonella, diplomatic conflict between Italy and the United States.
=== Other === Bone grafts are used in hopes that the defective bone will be healed or will regrow with little to no graft rejection. Besides the main use of bone grafting – dental implants – this procedure is used to fuse joints to prevent movement, repair broken bones that have bone loss, and repair broken bone that has not yet healed. Furthermore, bone grafts or substitutes are widely used for augmentation of spinal fusion procedures.
The doctor who had ordered the tests was a diabetes expert who specialised in insulin and hypoglycaemic episodes, and she had believed the incident to be suspicious. No doctor or medical staff member had prescribed her this drug, and she had no condition that required it to be issued. The amount of insulin in Hall's blood was about 12 times the normal level, and it had been injected into her system. The insulin was manufactured and not produced naturally in the body. It had been injected into her abdomen, as indicated by the fact that a bulge was found under her skin there that was consistent with a large injection of fluid. Doctors believed it was done by someone with nursing or medical experience. The results of the tests led the hospital to contact the police. It was discovered after Hall's death that insulin had also been taken from the storage fridge, and Norris later admitted that he was the last person to have accessed this fridge before Hall had been injected with insulin. Two vials of insulin were found to have been taken from the fridge, which had to have been taken by someone during the night shift which Norris was working when Hall became unwell. Norris had on a previous occasion been caught stealing drugs from the hospital. Norris also admitted that he was the last person to see Hall at 4.30 am, half an hour before she fell into the hypoglycaemic coma. at around 5 am.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.